Cat. No.: HY-190898

7Et-11F-CPT

7Et-11F-CPT is a Topoisomerase I inhibitor and an analog of 11F-CPT (HY-190897). 7Et-11F-CPT stabilizes the TOP I‑DNA cleavage complex in a non-covalent manner, promotes TOP I-related DNA damage, and activates the ATR-CHK1 DNA damage response. 7Et-11F-CPT induces cell cycle arrest predominantly in S phase accompanied by G2/M phase, upregulates Bax, Bad, and cleaved caspase‑3, and downregulates Bcl‑2, thereby inducing tumor cell apoptosis. 7Et-11F-CPT inhibits tumor growth in the PAN02 pancreatic cancer xenograft model. 7Et-11F-CPT can be used for research on pancreatic cancer.

For research use only. We do not sell to patients.

CAS No.: 124622-78-2
Formula: C₂₂H₁₉FN₂O₄
Molecular Weight:394.40

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

7Et-11F-CPT Chemical Structure

CAS No.: 124622-78-2

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

Topoisomerase I

Caspase 3

Bax

bad

Bcl-2

All Topoisomerase Isoforms :

All Bcl-2 Family Isoforms :

All Caspase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC50	0.152 μM	Antiproliferative activity against human HepG2 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human HepG2 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
A549	IC50	0.020 μM	Antiproliferative activity against human A549 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human A549 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
MCF7	IC50	0.102 μM	Antiproliferative activity against human MCF-7 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human MCF-7 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
SW480	IC50	0.045 μM	Antiproliferative activity against human SW480 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human SW480 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
T-24	IC50	0.005 μM	Antiproliferative activity against human T24 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human T24 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
UMUC3	IC50	0.001 μM	Antiproliferative activity against human UMUC3 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human UMUC3 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
PANC-1	IC50	0.087 μM	Antiproliferative activity against human PANC-1 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human PANC-1 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
BXPC-3	IC50	0.0002 μM	Antiproliferative activity against human BxPC-3 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human BxPC-3 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
L02	IC50	0.021 μM	Cytotoxicity against human L02 cells assessed as viability reduction incubated 48 hrs by MTT assay. Cytotoxicity against human L02 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683

In Vitro

Anti-cancerApoptosisCell Cycle RegulationOthers

Anti-cancer

7Et-11F-CPT (compound W12) (48 h) exhibits potent antiproliferative activity in the tested cancer cell lines, with the lowest IC₅₀ in BxPC-3 cells (0.0002 μM)^[1].
7Et-11F-CPT (0.01-0.25 μM in BxPC-3; 0.1-2.5 μM in PANC-1; 24 h-14 days) inhibits BxPC-3 and PANC-1 cell proliferation in the EdU incorporation assay and inhibits long-term colony formation^[1].
7Et-11F-CPT (48 h) induces γ-H2AX-positive DNA damage in BxPC-3 cells at 0.01 μM and in PANC-1 cells at 0.1 μM^[1].
7Et-11F-CPT induces DNA damage and activates ATR-CHK1 signaling^[1].
7Et-11F-CPT binds to TOP I in BxPC-3 cells and increases its thermal stability, promoting the trapping of TOP I on DNA in BxPC-3 cells^[1].
7Et-11F-CPT (0.5 μM in BxPC-3; 2.5 μM in PANC-1) inhibits cellular TOP I activity in BxPC-3 and PANC-1 cells^[1].

Anti-cancer

Apoptosis

7Et-11F-CPT (0.01-0.25 μM in BxPC-3; 0.1-2.5 μM in PANC-1; 48 h) induces apoptosis in BxPC-3 and PANC-1 cells in a dose-dependent manner, promotes pro-apoptotic protein signaling and decreases Bcl-2, and increases γ-H2AX protein levels^[1].

Anti-cancer

Cell Cycle Regulation

7Et-11F-CPT (0.01-0.25 μM in BxPC-3; 0.1-2.5 μM in PANC-1; 24 h) induces S-phase accumulation in BxPC-3 and PANC-1 cells, alters the expression of cell cycle regulatory proteins, and causes a more pronounced G2/M phase arrest than TPT^[1].

Others

7Et-11F-CPT inhibits purified human TOP I-mediated DNA relaxation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

BxPC-3 and PANC-1 cells
Concentration:

BxPC-3: 0.01, 0.05, 0.25 μM; PANC-1: 0.1, 0.5, 2.5 μM
Incubation Time:

24 h (EdU)
14 days (colony)
Result:

Inhibited the proliferation of BxPC-3 and PANC-1 cells—as demonstrated in EdU incorporation assays—and suppresses long-term colony formation.

Cell Cycle Analysis^[1]

Cell Line:

BxPC-3 and PANC-1 cells
Concentration:

BxPC-3: 0.01, 0.05, 0.25 μM; PANC-1: 0.1, 0.5, 2.5 μM
Incubation Time:

24 h
Result:

Induced S-phase accumulation in BxPC-3 and PANC-1 cells, with S-phase fractions reaching 90.0% in BxPC-3 at 0.25 μM and 76.7% in PANC-1 at 0.1 μM.

Western Blot Analysis^[1]

Cell Line:

BxPC-3 and PANC-1 cells
Concentration:

BxPC-3: 0.01, 0.05, 0.25 μM; PANC-1: 0.1, 0.5, 2.5 μM
Incubation Time:

24 h
Result:

Increased p53 and p21 expression, increased S-phase-related CCNA1 and G2/M-related CCNB1 expression.
Decreased G1-phase-related CCND1 and CCNE1 expression in a dose-dependent manner in both cell lines.

Apoptosis Analysis^[1]

Cell Line:

BxPC-3 and PANC-1 cells
Concentration:

BxPC-3: 0.01, 0.05, 0.25 μM; PANC-1: 0.1, 0.5, 2.5 μM
Incubation Time:

48 h
Result:

Induced apoptosis in BxPC-3 and PANC-1 cells in a dose-dependent manner, reaching 61.4% total apoptosis in BxPC-3 at 0.25 μM.

Western Blot Analysis^[1]

Cell Line:

BxPC-3 and PANC-1 cells
Concentration:

BxPC-3: 0.01, 0.05, 0.25 μM; PANC-1: 0.1, 0.5, 2.5 μM
Incubation Time:

48 h
Result:

Increased pro-apoptotic Bad, Bax, and cleaved caspase-3 expression and decreased anti-apoptotic Bcl-2 expression in a dose-dependent manner in both cell lines.
Increased γ-H2AX protein expression in both BxPC-3 and PANC-1 cells.

Immunofluorescence^[1]

Cell Line:

BxPC-3 and PANC-1 cells
Concentration:

BxPC-3: 0.01 μM; PANC-1: 0.1 μM
Incubation Time:

48 h
Result:

Substantially increased the proportion of γ-H2AX-positive cells in BxPC-3 and PANC-1 cells.

In Vivo

Anti-cancer

7Et-11F-CPT (compound W12) (1.5-4.5 mg/kg; intraperitoneal injection; every other day; 14 days) inhibits the growth of PAN02 syngeneic tumors in mice, with a tumor growth inhibition rate of 69.25% at 1.5 mg/kg and 80.78% at 4.5 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6J (female, 2 × 10⁶ PAN02 cells in 150 μL)^[1]
Dosage:

1.5 mg/kg and 4.5 mg/kg
Administration:

intraperitoneal; every other day; seven doses over 14 days
Result:

Suppressed PAN02 syngeneic tumor growth in mice, with tumor growth inhibition of 69.25% at 1.5 mg/kg and 80.78% at 4.5 mg/kg.

Related Protocols :

Chemical Information

CAS No. 124622-78-2
Molecular Weight 394.40
Formula C₂₂H₁₉FN₂O₄
SMILES

O=C1C2=C([C@](CC)(O)C(OC2)=O)C=C3C4=NC5=CC(F)=CC=C5C(CC)=C4CN31
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Chen GS, et al. Design, Synthesis, and Biological Evaluation of Novel, Fluorinated Camptothecin Derivatives as Potential Topoisomerase I Inhibitors. Journal of medicinal chemistry. 2026 Oct 22;69(20):24030-24052. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

7Et-11F-CPT

All Topoisomerase Isoforms

All Bcl-2 Family Isoforms

All Caspase Isoforms